Trial Profile
Phase I safety, pharmacokinetic, and pharmacodynamic study of KW-0761 in CC chemokine-receptor 4 expressing peripheral T-cell lymphoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Mogamulizumab (Primary)
- Indications Adult T-cell leukaemia-lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Kyowa Hakko Kirin; Kyowa Hakko Kogyo; Kyowa Kirin
- 16 Dec 2019 Results assessing population pharmacikinetic modeling by using data from six studies including this study published in the Journal of Clinical Pharmacology.
- 01 Oct 2017 Results of pooled data from two trial (NCT00920790 and NCT00355472) assessing efficacy of mogamulizumab in patient with relapsed adult T-cell leukemia-lymphoma, were published in the Cancer Science.
- 12 Dec 2011 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.